Jeff Leighton, Ph.D. stated, "After more than twelve years of service on the Icagen Board, I have decided to retire from this position entirely for family reasons."

"It has been a privilege to work with the management team and the Board of Directors at Icagen during this period."

"I continue to believe strongly in the approach of targeting ion channels for the development of novel pharmaceuticals and believe that Icagen is extremely well positioned to continue its research and development efforts in this field."

P. Kay Wagoner, Ph.D., Chief Executive Officer of Icagen, noted, "We thank Jeff for his many years of service on the Icagen Board. Since the Company's inception in 1992, his guidance and counsel have been invaluable."

"Jeff's presence on the Icagen Board will be greatly missed, and we wish him the very best in all his future endeavors. At the same time, we are delighted that Charles Sanders has been appointed our new Chairman."

"His many years of experience in the pharmaceutical industry and medical community will be of great value to the Company as we continue our mission to discover and develop novel pharmaceuticals based upon our core ion channel technology platform."

Dr. Sanders commented, "I thank the Board for this opportunity to serve as Chairman, and look forward to continuing to work with the management team and Board at Icagen as the Company continues to advance its pipeline of clinical and preclinical compounds."

"Speaking for the entire Board, I wish Jeff the very best, and thank him for his many years of dedicated service to the Company."